Skip to main content
. Author manuscript; available in PMC: 2010 Nov 8.
Published in final edited form as: Cancer Gene Ther. 2007 Dec 14;15(2):115–125. doi: 10.1038/sj.cgt.7701110

Figure 5. Delayed treatment with vvDD resulted in both decreased tumor burden and prolonged survival in a xenograft model of peritoneal carcinomatosis.

Figure 5

(a) Nude mice were injected with 1.0 × 106 human ovarian cancer A2780 cells to allow for growth of peritoneal ovarian tumors. On day 10 following inoculation of tumor cells, 1.0 × 108 pfu of vvDD was administered i.p. The toxicity of the virus and the growth of tumor and survival of mice were monitored daily. The survival data were analyzed by log rank test (p < 2.0 × 10e-5; control vs. vvDD). (b). The appearance and tumor growth of representative mice in both control and treated groups. Shown are one mouse in control group on day 79 and a vvDD virus-treated mouse on day 120.